In addition, new antibiotics with greater activity and a better toxicity profile against MDR Gram-negative bacilli are now available, such as ceftolozane–tazobactam, cefiderocol [34,35], or beta-lactam combinations with new beta-lactamase inhibitors [36]—such as ceftazidime–avibactam—that could improve the evolution of infections caused by MDR Gram-negative microorganisms in KT recipients. This evidence concerns the gene LACTB and infection.